4SC AG Enterprise value
What is the Enterprise value of 4SC AG?
The Enterprise value of 4SC AG is -$12.03
What is the definition of Enterprise value?
Enterprise value is a measure of a company’s total market value. It is calculated as market capitalization with debt, minority interest, and preferred shares minus total cash and cash equivalents.
ttm (trailing twelve months)
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Enterprise value of companies in the Health Care sector on XETRA compared to 4SC AG
What does 4SC AG do?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Companies with enterprise value similar to 4SC AG
- Hydraulique P.B Societe anonyme has Enterprise value of -$12.42
- Brand Architekts plc has Enterprise value of -$12.30
- Ocean Line Port Development has Enterprise value of -$12.28
- Neptune Wellness Solutions has Enterprise value of -$12.24
- Wisdom Sports has Enterprise value of -$12.18
- Orphazyme A/S has Enterprise value of -$12.12
- 4SC AG has Enterprise value of -$12.03
- Trilogy International Partners has Enterprise value of -$12.02
- Watchstone Plc has Enterprise value of -$11.75
- 360 Ludashi has Enterprise value of -$11.41
- KOALA has Enterprise value of -$11.26
- Sing Tao News has Enterprise value of -$11.07
- Amuse has Enterprise value of -$10.86